See what others are discussing and join the conversation.
Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer Dec 12, 2024 Dr. Aditya Bardia discusses Enhertu for metastatic hormone receptor-positive, HER2-low and -ultralow breast cancer and explains those terms. At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program…
Enhertu Beats Chemotherapy for HER2-Low and -Ultralow Metastatic Breast Cancer Jun 17, 2024 Enhertu seems better than chemotherapy for metastatic breast cancers with even the lowest detectable levels of HER2. Read more…
Enhertu Beats Chemotherapy for HER2-Low and -Ultralow Metastatic Breast Cancer Jun 17, 2024 Enhertu offers better survival than chemotherapy for pre-treated, metastatic, HER2-low or -ultralow breast cancer. Read more…
I'm making a list of questions for my oncologist appointment coming up and in looking at posts relative to metformin I came across neratinib. I realize the metformin trial ended up demonstrating that it was not beneficial in lessening recurrence rates. But apparently neratinib trials were because it was approved by the FDA…
It looks like you're new here. Sign in or register to get started.
These posts are awaiting responses - can you help?
Our Community Director reflects on conversations with members of our young with MBC support group about giving themselves time and grace.
Community Director Melissa Jenkins offers advice for responding to the gap between well-meant intentions and their negative impact.
Community Director Melissa Jenkins offers perspective on learning to trust your body again after a breast cancer diagnosis.
Browse our merchandise
We'd love to hear it.